🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Oesophageal Cancer

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma NCT06342167Phase 210 sites📍 Beijing📍 Fujian📍 Handan Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers NCT02584244Phase 1, Phase 21 site📍 Boston Lumicell, Inc. · Tests: LUM015, LUM 2.6 Imaging Device Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy NCT07104214n/a3 sites📍 Hangzhou📍 Jiaxing📍 Lishui Zhejiang University An Evaluation of Dose-escalation for Intrathoracic Tumours NCT06794125NA4 sites📍 Kelowna📍 Saint John📍 London Chris Goodman · Tests: Hypofractionated Radiation Therapy, Radiation Therapy Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining NCT00242723n/a1 site📍 Bethesda National Cancer Institute (NCI) Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: adebrelimab A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites📍 Birmingham📍 Birmingham📍 Birmingham Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046054, pembrolizumab A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer NCT07455019Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy Registry Platform Gastric/Esophageal Cancer (SAPHIR) NCT04290806n/a1 site📍 Multiple Locations iOMEDICO AG · Tests: Routine care as per site standard Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients NCT07114627n/a1 site📍 Rotterdam Erasmus Medical Center · Tests: Blood sampling for pharmacokinetics Lucid Registry Study NCT05965999n/a1 site📍 Lake Forest Lucid Diagnostics, Inc. · Tests: EsoCheck®, EsoGuard® A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma NCT06753747Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D) Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study NCT07437898Phase 21 site📍 Putian The Affiliated Hospital of Putian University · Tests: Adebrelimab, chemotherapy Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma NCT07595770Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy AI-Assisted Non-Contrast CT for Multi-Cancer Screening NCT06632886NA1 site📍 Shanghai Guo ShiWei · Tests: AI-Assisted Non-Contrast CT for Multi-Cancer Screening A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) NCT06232083Phase 11 site📍 Hefei Anhui Provincial Hospital · Tests: PLDR+Cardunizumab Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux NCT06746623NA1 site📍 Cleveland Louis Stokes VA Medical Center · Tests: Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy. Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer NCT06173986Phase 1, Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） NCT07354295n/a1 site📍 Wuhan Shu Peng A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) NCT05865002Phase 137 sites📍 Vijayawada📍 Visakhapatnam📍 Chandigarh Aurigene Discovery Technologies Limited · Tests: AUR107 PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer NCT06086457Phase 31 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383Phase 2, Phase 31 site📍 Beijing Shanghai JMT-Bio Inc. · Tests: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms NCT06687603NA5 sites📍 Aurora📍 Baltimore📍 Chapel Hill Case Comprehensive Cancer Center · Tests: EsoCheck, EsoGuard Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma NCT06596954NA1 site📍 Shanghai Ruijin Hospital · Tests: lymphocyte-sparing radiotherapy, conventional radiotherapy Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer NCT07632079Phase 27 sites📍 Amsterdam📍 Apeldoorn📍 Apeldoorn Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: Hypofractionation, carboplatin + paclitaxel (CP) Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma NCT06718205Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Nimotuzumab, Sintilimab, Paclitaxel-albumin, Cisplatin Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions NCT06476678n/a1 site📍 Houston Baylor College of Medicine · Tests: Speedboat™ Ultraslim Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. NCT05624099Phase 21 site📍 Fuzhou Fujian Cancer Hospital · Tests: camrelizumab, Paclitaxel drugs, Platinum drug, Radiation Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques NCT07035587n/a1 site📍 Seoul Yonsei University · Tests: Serial Blood Sampling for Molecular Profiling, One-Time Blood Sampling for Molecular Profiling
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy